Impaired retinoic acid signalling may lead to AD pathologyEvidence for overall mechanistic effect (in vitro)Evidence for reduction in inflammation, Aβ burden and tau phosphorylation with associated cognitive benefit, although studies are conflicting (in vitro)No clinical dataSignificant safety concerns. This evidence concerns the gene MAPT and Alzheimer disease.